Video

Dr. Lowentritt on choosing the right therapies for patients with mCSPC

Author(s):

Urology Times staff

“I think we're at a point where we have this luxury of many options, which is great, but we still need to continue to be really thoughtful in how we choose those options,” says Benjamin Lowentritt, MD, FACS.

In this video, Benjamin Lowentritt, MD, FACS, discusses the takeaways of the study, “Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Lowentritt is the director of minimally invasive surgery and robotics and the director of the Prostate Cancer Care Program at Chesapeake Urology in Baltimore, Maryland.

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Related Content
Study shows IsoPSA’s predictive ability for clinically significant prostate cancer
April 23rd 2025

Study shows IsoPSA’s predictive ability for clinically significant prostate cancer

Hannah Clarke
"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Urologists perform first remote robot–assisted HIFU for prostate cancer
April 17th 2025

Urologists perform first remote robot–assisted HIFU for prostate cancer

Hannah Clarke
“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Study underway to assess 3-fraction SBRT regimen in prostate cancer
April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | Image Credit: @ Dr_Microbe - stock.adobe.com
April 10th 2025

Polygenic risk score may identify more clinically significant PCa than PSA, MRI

Hannah Clarke
"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.
© 2025 MJH Life Sciences

All rights reserved.